ARYx Therapeutics is a technology company.
ARYx Therapeutics has raised $30.0M across 1 funding round.
ARYx Therapeutics has raised $30.0M in total across 1 funding round.
ARYx Therapeutics has raised $30.0M in total across 1 funding round.
ARYx Therapeutics's investors include Digitalis Ventures.
ARYx Therapeutics, Inc. (OTCPK:ARYX) is a biopharmaceutical company focused on discovering and developing novel oral therapies for large, chronic markets using its proprietary RetroMetabolic Drug Design technology, which creates structurally unique molecules that mimic the efficacy of existing drugs while aiming to reduce side effects.[1] The company targets conditions like blood clotting and atrial fibrillation with key pipeline assets including Tecarfarin (ATI-5923), an oral anticoagulant in Phase III for patients at risk of dangerous blood clots, and Budiodarone (ATI-2042), an antiarrhythmic agent in Phase IIb for atrial fibrillation.[1] Despite no reported revenue and ongoing losses (TTM earnings: -$18.33M), it maintains a minimal market cap of $33, reflecting its early-stage development status with products still in clinical trials.[1]
Founded in 1997, ARYx Therapeutics emerged as a biotech innovator leveraging RetroMetabolic Drug Design to redesign established drugs for improved safety profiles in chronic oral therapies.[1] The company's backstory centers on addressing limitations in existing treatments for cardiovascular and related disorders, with early efforts leading to a portfolio of small-molecule drugs now spanning Phase I to III trials.[1][2] Pivotal moments include advancing Tecarfarin to Phase III and Budiodarone to Phase IIb, alongside discontinued projects like Naronapride for postprandial distress and SPM-928 for cardiac arrhythmias, highlighting a focus on iterative pipeline refinement.[2]
ARYx rides the wave of precision drug redesign in biotech, where technologies like RetroMetabolic enable "best-in-class" iterations of blockbuster drugs amid rising demand for safer chronic therapies in aging populations.[1] Timing aligns with post-pandemic emphasis on cardiovascular health, as atrial fibrillation and clotting risks surge globally, bolstered by market forces favoring oral alternatives to injectables.[1][2] By influencing the ecosystem through Phase III assets, ARYx contributes to anticoagulant innovation, potentially pressuring incumbents like warfarin derivatives while highlighting biotech's shift toward metabolic and arrhythmia solutions in a $100B+ cardiovascular market.
ARYx's path hinges on Tecarfarin Phase III readout and potential partnerships to fund Budiodarone's next steps, amid a lean operation with zero revenue but active trials.[1][2] Trends like AI-driven drug design and cardio-metabolic focus could accelerate its molecules, though financial health risks (low scores across metrics) demand capital raises or acquisitions.[1] Influence may evolve via approvals or buyouts by big pharma seeking oral anticoagulant pipelines, positioning ARYx as a niche player in chronic therapy redesign—or a cautionary tale if trials falter—ultimately testing its technology against biotech's high-stakes innovation cycle.[1][2]
ARYx Therapeutics has raised $30.0M across 1 funding round. Most recently, it raised $30.0M Series E in February 2006.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2006 | $30.0M Series E | Digitalis Ventures |